Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-06T00:57:52.170Z Has data issue: false hasContentIssue false
  • English
  • Français

Myopathy in Primary Systemic Amyloidosis

Published online by Cambridge University Press:  18 September 2015

M.E. Roke ,
W.F.E. Brown ,
D. Boughner ,
L.C. Ang  and
G.P.A. Rice
M.E. Roke
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London
W.F.E. Brown
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London
D. Boughner
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London
L.C. Ang
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London
G.P.A. Rice*
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London
*
Clinical Neurological Science Department, University Hospital, P.O. Box 5339, Postal Station A, London, Ontario, Canada N6A 5A5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Involvement of the peripheral nervous system by amyloidosis is common. It is less well recognized that amyloid can directly infiltrate and weaken skeletal muscle. We report a case of a 73-year-old woman, known to have cardiac amyloidosis, who developed profound weakness secondary to amyloid myopathy. Review of the 8 other well documented cases in the literature has revealed a rather homogeneous syndrome. Proximal weakness, muscle stiffness, pseudohypertrophy and myalgia constitute the principal features. This syndrome usually develops in cases with well recognized generalized amyloidosis. Amyloid is deposited within the basal lamina of blood vessels and muscle fibers.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 15 , Issue 3 , August 1988 , pp. 314 - 316
Copyright
Copyright © Canadian Neurological Sciences Federation 1988

References

REFERENCES

1.Kyle, RA, Greipp, PR. Amyloidosis. Mayo Clin Proc 1983; 58: 665–683.Google ScholarPubMed
2.Baker, B and Engel, A. Myology. McGraw–Hill, 1986; 887–891; 1029–1036; 2098–2099.Google Scholar
3.Whitaker, JN, Hashimoto, K, Quiñones, Met al. Skeletal muscle pseudohypertrophy in primary amyloidosis. Neurology 1977; 27: 47–54.CrossRefGoogle ScholarPubMed
4.Ringel, SP, Chaman, HN. Amyloid associated pseudohypertrophy. Arch Neurol 1982; 39: 413–417.CrossRefGoogle ScholarPubMed
5.Lubarsch, D. “Zur kenntnis eingenhohnlicher amyloidablagerum-gen” Virchows Arch 1929; 271: 867–889.CrossRefGoogle Scholar
6.Reichenmiller, HE, Bundschu, HD, Bass, L, et al. Progressive muscular dystrophy and pericollagenous amyloidosis. German Medical Monthly 1968; 13: 380–384.Google ScholarPubMed
7.Martin, JJ, Van Bogaert, L, Van Damme, J, et al. Sur un pseudo-myopathie ligneuse généralisée par Amyloidose primaire endomysio-vasculaire. J Neurol Sci 1970; 11: 147–160.CrossRefGoogle Scholar
8.Bruni, J, Bilbao, JM, Pritzker, KPH. Myopathy associated with amy-loid angiopathy. Can J Neurol Sci 4(1): 1977; 77–80.CrossRefGoogle Scholar
9.Miyasacki, K, Murao, S, Tsunetoshi, S, et al. Primary systemic amy-loidosis. Acta Pathol Jpn, 29 (1): 1979; 157–169.Google Scholar
10.Li, K, Hizawa, K, Morizumi, H, et al. Primary Systemic Amyloidosis. Arch Path 1984; 39: 315–322.Google Scholar
11.Lange, K. Primary Amyloidosis of Muscle. Southern Med J 1974; 63: 321–323.CrossRefGoogle Scholar
12.Bendagen, M. ProteinA-gold electron microscopic immunocyto-chemistry: methods, applications and limitations. J Electron Microscopy Technique 1984; 1:243–270.CrossRefGoogle Scholar
13.Mair, WGP, Tome, FMS. Atlas of the ultrastructure of disease of human muscle. (Churchill Livingston, London, 1972).Google Scholar
14.Andrade, C. A peculiar form of peripheral neuropathy. Brain 1952; 75; 408–427.CrossRefGoogle ScholarPubMed
15.Ravid, M, Robson, M, Kedar, I, et al. Prolonged cochicine treatment in four patients with amyloidosis. Ann Int Med 1977; 87: 568–570.CrossRefGoogle Scholar
16.Kyle, RA, Greipp, PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood, 1978; 52 (4): 818–827.CrossRefGoogle ScholarPubMed
17.Kyle, RA, Greipp, PR, Garton, JPet al. Primary systemic amyloido-sis. Am J Med 1985; 79: 708–716.CrossRefGoogle Scholar
18.Zewar, D, Pras, M, Sohar, E, et al. Colchicine in prevention and treatment of the amyloidosis of familial mediterranean fever. N Eng J Med 314 (16): 1986; 1002–1004.Google Scholar
19.Delaporte, C, Varet, B, Fardeau, M, et al. In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy. J Clin Invest 1986; 78: 922–927.CrossRefGoogle ScholarPubMed